NanoTech Institute

NanoTech Institute
Name	NanoTech Institute
Established	2004
Type	University-affiliated research center
Director	Dr. Elena Vance
City	San Francisco
State	California
Country	United States
Affiliations	UCSF, Lawrence Berkeley National Laboratory

NanoTech Institute. Founded in 2004 through a joint initiative between the UCSF School of Medicine and the Lawrence Berkeley National Laboratory, the institute has established itself as a premier interdisciplinary hub for nanotechnology research with biomedical applications. Under the leadership of founding director Dr. Elena Vance, it has pioneered novel approaches at the intersection of materials science, molecular biology, and precision medicine. The institute's work is characterized by a strong translational focus, aiming to bridge the gap between fundamental nanoscale discovery and clinical implementation.

History

The concept for the institute emerged from strategic discussions in the early 2000s among leadership at UCSF and scientists at the Lawrence Berkeley National Laboratory, who recognized the untapped potential of nanotechnology for oncology and regenerative medicine. Its establishment in 2004 was catalyzed by a major grant from the National Institutes of Health's National Cancer Institute as part of the Alliance for Nanotechnology in Cancer initiative. The institute's first laboratories were housed in the newly constructed Mission Bay research campus of UCSF, facilitating close ties with clinical departments. A significant expansion occurred in 2012 with the completion of the Advanced Materials Research Wing, funded by a donation from the Gordon and Betty Moore Foundation.

Research focus

Core research is organized around three primary, synergistic thrusts. The first is theranostic nanoparticles, which combine diagnostic imaging agents like those used in MRI with targeted therapeutic payloads for diseases such as glioblastoma and metastatic breast cancer. The second thrust involves the development of nanofabricated scaffolds for tissue engineering, particularly for cardiac tissue repair post-myocardial infarction and neural regeneration. The third major focus is on single-molecule detection platforms using nanopore and surface-enhanced Raman spectroscopy (SERS) techniques for the early diagnosis of pathogens like SARS-CoV-2 and biomarkers for Alzheimer's disease.

Key facilities and equipment

The institute operates several state-of-the-art, shared resource facilities central to its mission. The Nanofabrication Cleanroom, a Class 100 environment, houses multiple electron-beam lithography systems and a molecular beam epitaxy chamber for creating precise nanostructures. The Advanced Imaging Suite features a cryo-electron microscope, a super-resolution microscope, and a 7-tesla MRI scanner dedicated to small-animal research. The Biomaterials Characterization Core is equipped with atomic force microscopy, dynamic light scattering, and X-ray photoelectron spectroscopy instruments for analyzing material properties. These facilities are also utilized by partners from Stanford University and the Chan Zuckerberg Biohub.

Notable achievements

Researchers published a landmark 2010 paper in *Nature Nanotechnology* demonstrating the first successful use of gold nanorods for the photothermal ablation of tumors in mouse models, a technology later licensed to Gilead Sciences. In 2016, a team led by Dr. Arun Mehta developed a nanomesh electronic sensor that can seamlessly integrate with the surface of the heart for continuous, high-fidelity monitoring, earning the team the IEEE EMBS Translational Award. Another breakthrough, published in *Science* in 2021, detailed a DNA origami-based drug delivery system capable of bypassing the blood-brain barrier to treat medulloblastoma, leading to an ongoing Phase I clinical trial at Memorial Sloan Kettering Cancer Center.

Collaborations and partnerships

The institute maintains a robust network of academic, clinical, and industrial partnerships. A long-standing collaboration with the Massachusetts Institute of Technology's Koch Institute for Integrative Cancer Research focuses on immunotherapy delivery systems. Within the Bay Area, close ties exist with the Gladstone Institutes for cardiovascular disease projects and the Buck Institute for Research on Aging for senescence-targeting nanotherapies. Industrial alliances include a multi-year research agreement with Roche for diagnostics development and a joint venture with Boston Scientific on bioabsorbable stents. The institute also participates in the European Union's Graphene Flagship program.

Educational programs

Beyond research, the institute is deeply committed to training the next generation of scientists. It administers a prestigious NSF-funded Integrative Graduate Education and Research Traineeship (IGERT) program in Nanomedicine, which includes students from UCSF, UC Berkeley, and UC Santa Cruz. The annual Frontiers in Nanotechnology summer school attracts doctoral candidates and postdoctoral fellows from institutions worldwide, including ETH Zurich and the University of Tokyo. Furthermore, the institute runs the Bay Area Nano Explorers outreach initiative, which brings hands-on demonstrations to local high schools such as Lowell High School and the San Francisco University High School.

Category:Research institutes in California Category:Nanotechnology organizations Category:University of California, San Francisco